3 ms·
That's what I read in AstraZeneca press-release. > The MHRA’s decision was based on ... _interim_ analysis of the Phase III programme > Additional safety and
by oytis 6y ago
That's what I read in AstraZeneca press-release.
> The MHRA’s decision was based on ... _interim_ analysis of the Phase III programme
> Additional safety and efficacy data for the vaccine will continue to accumulate from _ongoing_ clinical trials.
https://www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html https://www.astrazeneca.com/media-centre/press-releases/2020...